Through the Reader lens — Johnson & Johnson has agreed to a $5.5 billion global settlement to resolve roughly 76,000 lawsuits alleging that its talc-based baby powder caused ovarian cancer, marking one of the largest consumer-product resolutions in recent years. The deal does not constitute an admission of wrongdoing but is designed to extinguish a years-long litigation overhang that has shadowed the company’s consumer brands and product strategy. Both Indian-language outlets (Aaj Tak, Amar Ujala) frame the story neutrally around the payout and claim count, with no competing narratives or partisan commentary present in the provided sources. For affected claimants, the settlement unlocks a defined compensation path; for J&J, it converts uncertain legal risk into a known, multi-billion cash hit that will weigh on near-term financials but removes tail risk. Coverage is thin on implementation mechanics—eligibility windows, payment timelines, and whether non-participating claimants remain active are not detailed here. Watch for court approvals, the share of claimants that elect into the settlement, and any residual suits that fall outside the agreement.